Workboat Indexes

Novo Nordisk A/S ADR (NY: NVO )

133.28 +0.10 (+0.08%)

Official Closing Price Updated: 7:00 PM EDT, Jul 23, 2024 Add to My Watchlist

Price and Volume

Volume	2,383,247
Open	133.56
Bid (Size)	133.15 (5)
Ask (Size)	134.50 (4)
Prev. Close	133.18
Today's Range	133.02 - 134.67
52wk Range	77.95 - 148.15
Shares Outstanding	N/A
Dividend Yield	1.33%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off

Today 15:05 EDT

Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The company's U.S. business has struggled with the rise of GLP-1 drugs and...

Via Benzinga

Britain's Drug Regulator Approves Novo Nordisk's Weight Loss Drug Wegovy To Cut Heart Disease Risk In Obese Patients

Today 14:40 EDT

The U.K. MHRA has approved Novo Nordisk's Wegovy (semaglutide) to prevent cardiovascular issues in overweight and obese adults with existing heart conditions. This new indication highlights Wegovy's...

Via Benzinga

Performance

YTD	+30.53%	+30.53%
1 Month	-6.33%	-6.33%
3 Month	+3.61%	+3.61%
6 Month	+26.49%	+26.49%
1 Year	+64.47%	+64.47%

More News

Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?

Today 5:48 EDT

Via The Motley Fool

Why Hims & Hers Heath Shares Are Surging Today

July 22, 2024

Via Benzinga

Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts

July 22, 2024

Via Benzinga

Novo Nordisk Options Trading: A Deep Dive into Market Sentiment

July 19, 2024

Via Benzinga

$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today

July 17, 2024

Via Benzinga

Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier

July 22, 2024

Via Benzinga

7 Sorry Biotech Stocks Set to Make Investors Sad

July 22, 2024

Via InvestorPlace

Here's My Top Growth Stock to Buy Right Now

July 20, 2024

Via The Motley Fool

3 Monster Stocks in the Making to Buy Right Now

July 20, 2024

Via The Motley Fool

Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications

July 19, 2024

Via Benzinga

Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review

July 19, 2024

Via Investor's Business Daily

Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval

July 19, 2024

Via Benzinga

7 A-Rated Stock Picks With Huge Upside Potential

July 19, 2024

Via InvestorPlace

Is Viking Therapeutics a Millionaire-Maker?

July 19, 2024

Via The Motley Fool

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'

July 18, 2024

Via Benzinga

VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?

July 18, 2024

Via Benzinga

AI Demand and New Deals Make Ginkgo Bioworks Stock a Speculative Buy

July 18, 2024

Via InvestorPlace

Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio

July 17, 2024

Via InvestorPlace

Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage

July 17, 2024

Via Benzinga

Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped

July 17, 2024

Via The Motley Fool

Pfizer And Roche Advance On Their Weight Loss Drug Journeys

July 17, 2024

Via Benzinga

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?

July 17, 2024

Via Benzinga

Eli Lilly, Novo Nordisk Fall As Roche Releases Weight-Loss Drug Data

July 17, 2024

Via Investor's Business Daily

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.